The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer

References

• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa05553116822992
   PubMed Web of Science ®Google Scholar
• Vale C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927–1934. doi:10.1016/S0140-6736(03)13580-512801735
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. doi:10.1056/NEJMoa04069415496622
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi:10.1056/NEJMoa111208822646630
   PubMed Web of Science ®Google Scholar
• Conroy T, Lamfichekh N, Etienne P-L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2020;38(15_suppl):4007. doi:10.1200/JCO.2020.38.15_suppl.4007
   Web of Science ®Google Scholar
• Hospers G, Bahadoer RR, Dijkstra EA, et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial. J Clin Oncol. 2020;38(15_suppl):4006. doi:10.1200/JCO.2020.38.15_suppl.4006
   Google Scholar
• Karoui M, Rullier A, Luciani A, et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial–the PRODIGE 22–ECKINOXE trial. BMC Cancer. 2015;15:511. doi:10.1186/s12885-015-1507-326156156
   PubMed Web of Science ®Google Scholar
• FoxTROT Collaborative Group. FOxTROT protocol: a randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable colon cancer; 2012. Available from: https://www.birmingham.ac.uk/Documents/college-mds/trials/bctu/foxtrot/FOxTROTProtocolv60090712.pdf. Accessed 1230, 2020.
   Google Scholar
• Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72. doi:10.1093/annonc/mdt35424078664
   PubMed Web of Science ®Google Scholar
• Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–3419. doi:10.1200/JCO.2004.05.06315199089
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-420180029
   PubMed Web of Science ®Google Scholar
• Labianca R, Marsoni S, Pancera G, et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345(8955):939–944.7715291
   PubMed Web of Science ®Google Scholar
• André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176–4187. doi:10.1200/JCO.2015.63.423826527776
   PubMed Web of Science ®Google Scholar
• André T, Meyerhardt J, Iveson T, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21(12):1620–1629. doi:10.1016/S1470-2045(20)30527-133271092
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–3774. doi:10.1200/JCO.2011.36.453921859995
   PubMed Web of Science ®Google Scholar
• Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–1733. doi:10.1016/S0140-6736(02)08651-812049861
   PubMed Web of Science ®Google Scholar
• Sebag-Montefiore D, Stephens RJ, Steele SR, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016) - a multicentre, randomised trial. Lancet. 2009;373:811–820. doi:10.1016/S0140-6736(09)60484-019269519
   PubMed Web of Science ®Google Scholar
• Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6(5):534–543. doi:10.3978/j.issn.2078-6891.2015.04726487948
   PubMedGoogle Scholar
• Graham PJ, Brar MS, Foster T, et al. Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. Ann Surg Oncol. 2015;22(10):3376–3382. doi:10.1245/s10434-015-4714-x26202561
   PubMed Web of Science ®Google Scholar
• Arredondo J, Baixauli J, Pastor C, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol. 2017;19(3):379–385. doi:10.1007/s12094-016-1539-427496023
   PubMed Web of Science ®Google Scholar
• Collaborative Group F; FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–1160. doi:10.1016/S1470-2045(12)70348-023017669
   PubMed Web of Science ®Google Scholar
• Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688–8696. doi:10.1200/JCO.2005.02.132916246976
   PubMed Web of Science ®Google Scholar
• Riva F, Bidard F-C, Houy A, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem. 2017;63(3):691–699. doi:10.1373/clinchem.2016.26233728073896
   PubMed Web of Science ®Google Scholar
• Yang L, Wang Y, Shen L, et al. Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: the potential use of ctDNA monitoring as organ-sparing approach. J Clin Oncol. 2018;36(15_suppl):3608. doi:10.1200/JCO.2018.36.15_suppl.3608
   Web of Science ®Google Scholar
• Tanaka K, Shimada H, Miura M, et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg. 2004;28(3):263–270. doi:10.1007/s00268-003-7088-314961200
   PubMed Web of Science ®Google Scholar
• Finlay IG, Meek D, Brunton F, McArdle CS. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg. 1988;75(7):641–644. doi:10.1002/bjs.18007507073416116
   PubMed Web of Science ®Google Scholar
• Scheer MG, Stollman TH, Vogel WV, Boerman OC, Oyen WJ, Ruers TJ. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med. 2008;49(6):887–891. doi:10.2967/jnumed.107.04837118483084
   PubMed Web of Science ®Google Scholar
• Zeamari S, Roos E, Stewart FA. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. Eur J Cancer. 2004;40(9):1431–1440. doi:10.1016/j.ejca.2004.01.03515177504
   PubMed Web of Science ®Google Scholar
• Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93(8):583–596. doi:10.1093/jnci/93.8.58311309435
   PubMed Web of Science ®Google Scholar
• Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum. 2010;53(12):1587–1593. doi:10.1007/DCR.0b013e3181f2f20221178851
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Inomata M, Katayama H, et al. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. Ann Surg. 2014;260(1):23–30. doi:10.1097/SLA.000000000000049924509190
   PubMed Web of Science ®Google Scholar
• de Gooyer JM, Verstegen MG, t Lam-Boer J, et al. Neoadjuvant chemotherapy for locally advanced T4 colon cancer: a nationwide propensity-score matched cohort analysis. Dig Surg. 2020;37(4):292–301. doi:10.1159/00050344631661689
   PubMed Web of Science ®Google Scholar
• Weinrich M, Bochow J, Kutsch AL, et al. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: a cohort study. Ann Med Surg (Lond). 2018;32:32–37. doi:10.1016/j.amsu.2018.06.00430034801
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–537. doi:10.1007/s10549-010-1132-420803066
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi:10.1038/s41591-020-0805-832251400
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Lonati V, Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis. 2015;30(4):447–457. doi:10.1007/s00384-014-2082-925433820
   PubMed Web of Science ®Google Scholar
• Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015;54(10):1747–1753. doi:10.3109/0284186X.2015.103700725920359
   PubMed Web of Science ®Google Scholar
• Ingraham AM, Cohen ME, Bilimoria KY, et al. Comparison of hospital performance in nonemergency versus emergency colorectal operations at 142 hospitals. J Am Coll Surg. 2010;210(2):155–165. doi:10.1016/j.jamcollsurg.2009.10.01620113935
   PubMed Web of Science ®Google Scholar
• Seymour MT, Morton D; on behalf of the International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 2019;37(15_suppl):3504. doi:10.1200/JCO.2019.37.15_suppl.3504
   Web of Science ®Google Scholar
• Zhou H, Song Y, Jiang J, et al. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res. 2016;28(6):598–605. doi:10.21147/j.issn.1000-9604.2016.06.0628174488
   PubMed Web of Science ®Google Scholar
• Liu F, Yang L, Wu Y, et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chin J Cancer Res. 2016;28(6):589–597. doi:10.21147/j.issn.1000-9604.2016.06.0528174487
   PubMed Web of Science ®Google Scholar
• Malmstrøm ML, Săftoiu A, Vilmann P, Klausen TW, Gögenur I. Endoscopic ultrasound for staging of colonic cancer proximal to the rectum: a systematic review and meta-analysis. Endosc Ultrasound. 2016;5(5):307–314. doi:10.4103/2303-9027.19161027803903
   PubMed Web of Science ®Google Scholar
• Malmstrøm ML, Gögenur I, Riis LB, et al. Endoscopic ultrasonography and computed tomography scanning for preoperative staging of colonic cancer. Int J Colorectal Dis. 2017;32(6):813–820. doi:10.1007/s00384-017-2820-x28432444
   PubMed Web of Science ®Google Scholar
• Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer. 2007;96(7):1030–1036. doi:10.1038/sj.bjc.660364617353925
   PubMed Web of Science ®Google Scholar
• Dighe S, Swift I, Magill L, et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Dis. 2012;14(4):438–444. doi:10.1111/j.1463-1318.2011.02638.x21689323
   PubMed Web of Science ®Google Scholar
• Dehal AN, Graff-Baker AN, Vuong B, et al. Correlation between clinical and pathologic staging in colon cancer: implications for neoadjuvant treatment. J Gastrointest Surg. 2018;22(10):1764–1771. doi:10.1007/s11605-018-3777-y29790087
   PubMed Web of Science ®Google Scholar
• Park SY, Cho SH, Lee MA, et al. Diagnostic performance of MRI- versus MDCT-categorized T3cd/T4 for identifying high-risk stage II or stage III colon cancers: a pilot study. Abdom Radiol. 2019;44(5):1675–1685. doi:10.1007/s00261-018-1822-7
   PubMed Web of Science ®Google Scholar
• Rollvén E, Holm T, Glimelius B, Lörinc E, Blomqvist L. Potentials of high resolution magnetic resonance imaging versus computed tomography for preoperative local staging of colon cancer. Acta Radiologica. 2013;54(7):722–730. doi:10.1177/028418511348401823550186
   PubMed Web of Science ®Google Scholar
• Nerad E, Lambregts DMJ, Kersten ELJ, et al. MRI for local staging of colon cancer: can MRI become the optimal staging modality for patients with colon cancer? Dis Colon Rectum. 2017;60(4):385–392. doi:10.1097/DCR.000000000000079428267005
   PubMed Web of Science ®Google Scholar
• Filippone A, Ambrosini R, Fuschi M, Marinelli T, Genovesi D, Bonomo L. Preoperative T and N staging of colorectal cancer: accuracy of contrast-enhanced multi-detector row CT colonography–initial experience. Radiology. 2004;231(1):83–90. doi:10.1148/radiol.231102115214990815
   PubMed Web of Science ®Google Scholar
• Komono A, Shida D, Iinuma G, et al. Preoperative T staging of colon cancer using CT colonography with multiplanar reconstruction: new diagnostic criteria based on “bordering vessels”. Int J Colorectal Dis. 2019;34(4):641–648. doi:10.1007/s00384-019-03236-y30666406
   PubMed Web of Science ®Google Scholar
• Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983;43(4):1488–1492.6831397
   PubMed Web of Science ®Google Scholar
• Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. 1989;49(8):2002–2004.2522814
   PubMed Web of Science ®Google Scholar
• Peeters CFJM, de Waal RMW, Wobbes T, Ruers TJM. Metastatic dormancy imposed by the primary tumor: does it exist in humans? Ann Surg Oncol. 2008;15(11):3308–3315. doi:10.1245/s10434-008-0029-518685897
   PubMed Web of Science ®Google Scholar
• Wang Y-J, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5(3):194–203. doi:10.1016/j.gendis.2018.05.00330320184
   PubMed Web of Science ®Google Scholar
• Dagenborg VJ, Marshall SE, Yaqub S, et al. Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biol Ther. 2020;21(5):432–440. doi:10.1080/15384047.2020.172125232098573
   PubMed Web of Science ®Google Scholar
• Ito F, Ku AW, Bucsek MJ, et al. Immune adjuvant activity of pre-resectional radiofrequency ablation protects against local and systemic recurrence in aggressive murine colorectal cancer. PLoS One. 2015;10(11):e0143370. doi:10.1371/journal.pone.014337026599402
   PubMed Web of Science ®Google Scholar
• Weeber F, van de Wetering M, Hoogstraat M, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A. 2015;112(43):13308–13311. doi:10.1073/pnas.151668911226460009
   PubMed Web of Science ®Google Scholar
• Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell. 2020;26(1):17–26. doi:10.1016/j.stem.2019.10.01031761724
   PubMed Web of Science ®Google Scholar
• Janakiraman H, Zhu Y, Becker SA, et al. Modeling rectal cancer to advance neoadjuvant precision therapy. Int J Cancer. 2020;147:1405–1418. doi:10.1002/ijc.3287631989583
   PubMed Web of Science ®Google Scholar
• Roy P, Canet-Jourdan C, Annereau M, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC. Int J Pharm. 2017;531(1):143–152. doi:10.1016/j.ijpharm.2017.07.08428803938
   PubMed Web of Science ®Google Scholar
• Salimath J, Jones MW, Hunt DL, Lane MK. Comparison of return of bowel function and length of stay in patients undergoing laparoscopic versus open colectomy. JSLS. 2007;11(1):72–75.17651560
   PubMedGoogle Scholar
• Kelly M, Sharp L, Dwane F, Kelleher T, Comber H. Factors predicting hospital length-of-stay and readmission after colorectal resection: a population-based study of elective and emergency admissions. BMC Health Serv Res. 2012;12(1):77. doi:10.1186/1472-6963-12-7722448728
   PubMed Web of Science ®Google Scholar
• Miller T, Thacker J, White W, et al. Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg. 2014;118:1052–1061. doi:10.1213/ANE.000000000000020624781574
   PubMed Web of Science ®Google Scholar
• Krarup P-M, Jorgensen LN, Andreasen AH, Harling H; Group obotDCC. A nationwide study on anastomotic leakage after colonic cancer surgery. Colorectal Dis. 2012;14(10):e661–e667. doi:10.1111/j.1463-1318.2012.03079.x22564292
   PubMed Web of Science ®Google Scholar
• Dehal A, Graff-Baker AN, Vuong B, et al. Neoadjuvant chemotherapy improves survival in patients with clinical T4b colon cancer. J Gastrointest Surg. 2018;22(2):242–249. doi:10.1007/s11605-017-3566-z28933016
   PubMed Web of Science ®Google Scholar
• Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–146. doi:10.1111/j.1365-2559.2005.02176.x16045774
   PubMed Web of Science ®Google Scholar
• Karoui M, Gallois C, Piessen G, et al. Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial. J Clin Oncol. 2020;38(15_suppl):4110. doi:10.1200/JCO.2020.38.15_suppl.4110
   Google Scholar
• Morton D. FOxTROT: an international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. Ann Oncol. 2019;30:v198–v252. doi:10.1093/annonc/mdz246.001
   Google Scholar
• Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15(6):601–611. doi:10.1016/S1470-2045(14)70105-624717919
   PubMed Web of Science ®Google Scholar
• Bridgewater JA, Pugh SA, Maishman T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398–411. doi:10.1016/S1470-2045(19)30798-332014119
   PubMed Web of Science ®Google Scholar
• Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(11):1543–1557. doi:10.1016/S1470-2045(16)30172-327660192
   PubMed Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497–507. doi:10.1016/S1470-2045(19)30862-932164906
   PubMed Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann Oncol. 2018;29(7):1528–1534. doi:10.1093/annonc/mdy14029873679
   PubMed Web of Science ®Google Scholar
• Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;38(28):3314–3324. doi:10.1200/JCO.20.01225
   Web of Science ®Google Scholar
• China Medical University. Neoadjuvant FOLFOXIRI chemotherapy in patients with locally advanced colon cancer. Available from: https://ClinicalTrials.gov/show/NCT03484195. Accessed 1214, 2020.
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa150059626028255
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-928734759
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773–779. doi:10.1200/JCO.2017.76.990129355075
   PubMed Web of Science ®Google Scholar
• Seligmann JF. FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC). J Clin Oncol. 2020;38(15_suppl):4013. doi:10.1200/JCO.2020.38.15_suppl.4013
   Google Scholar
• Liu D-X, Li -D-D, He W, et al. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncoimmunology. 2020;9(1):1711650. doi:10.1080/2162402X.2020.171165032042474
   PubMed Web of Science ®Google Scholar
• George E. People;s trial of PalloV-CC in colon cancer. Available from: https://ClinicalTrials.gov/show/NCT03827967. Accessed 1220 2020.
   Google Scholar
• Chang H, Yu X, Xiao -W-W, et al. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 2018;11:409–418. doi:10.2147/OTT.S15036729398921
   PubMed Web of Science ®Google Scholar
• Sun Yat-sen University. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for unresectable locally advanced colon cancer. Available from: https://ClinicalTrials.gov/show/NCT03970694. Accessed 1214, 2020.
   Google Scholar
• Cercek A, Dos Santos Fernandes G, Roxburgh CS, et al. Mismatch repair deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26(13):3271–3279. doi:10.1158/1078-0432.CCR-19-372832144135
   PubMed Web of Science ®Google Scholar
• Strowitzki MJ, Radhakrishnan P, Pavicevic S, et al. High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases. Br J Cancer. 2019;120(7):675–688. doi:10.1038/s41416-019-0406-930808993
   PubMed Web of Science ®Google Scholar
• Yang X, Zhu F, Yu C, et al. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2. Oncotarget. 2017;8(29):47709–47724. doi:10.18632/oncotarget.1771128537875
   PubMedGoogle Scholar
• Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011;71(15):5307–5316. doi:10.1158/0008-5472.CAN-11-022121652540
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Chiang S-F, Chen WT-L, et al. HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer. Cell Death Dis. 2018;9(10):1004. doi:10.1038/s41419-018-1019-630258050
   PubMed Web of Science ®Google Scholar
• Ju T, Jin H, Ying R, Xie Q, Zhou C, Gao D. Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells. Mol Med Rep. 2017;16(3):3194–3200. doi:10.3892/mmr.2017.698628713930
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER cancer stat facts: colorectal cancer; 2020. Available from: https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 113, 2020.
   Google Scholar
• Ishibe A, Watanabe J, Suwa Y, et al. A prospective, single-arm, multicenter trial of diverting stoma followed by neoadjuvant chemotherapy using mFOLFOX6 for obstructive colon cancer: YCOG 1305 (PROBE study). Ann Surg. 2020. doi:10.1097/SLA.0000000000004494
   PubMed Web of Science ®Google Scholar
• Hôpitaux de Paris. Trial of neoadjuvant chemotherapy in locally advanced colon cancer (ECKINOXE). Available from: https://ClinicalTrials.gov/show/NCT01675999. Accessed 1119, 2020.
   Google Scholar
• University of Birmingham. Fluorouracil and oxaliplatin with or without panitumumab in treating patients with high-risk colon cancer that can be removed by surgery (FOxTROT). Available from: https://ClinicalTrials.gov/show/NCT00647530. Accessed 1230, 2020.
   Google Scholar
• First Affiliated Hospital with Nanjing Medical University. Neoadjuvant chemotherapy for the treatment of resectable locally advanced colon cancer. Available from: https://ClinicalTrials.gov/show/NCT02882269. Accessed 1214, 2020.
   Google Scholar
• Kyungpook National University Hospital. Neoadjuvant FOLFOX chemotherapy for patients with locally advanced colon cancer NCT03426904. Available from: https://ClinicalTrials.gov/show/NCT03426904. Accessed 1215, 2020.
   Google Scholar
• Vejle Hospital. Neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer NCT03970694. Available from: https://ClinicalTrials.gov/show/NCT01918527. Accessed 1215, 2020.
   Google Scholar
• Universidad de Leon. Analysis of the effectiveness of neoadjuvant chemotherapy in the treatment of colon cancer locally advanced (ELECLA) NCT04188158. Available from: https://ClinicalTrials.gov/show/NCT04188158. Accessed 1215, 2020.
   Google Scholar
• WntResearch AB. Foxy-5 as neo-adjuvant therapy in subjects with wnt-5a low colon cancer. Available from: https://ClinicalTrials.gov/show/NCT03883802. Accessed 1220, 2020.
   Google Scholar
• Fudan University. Laparoscopic surgery vs laparoscopic surgery + neoadjuvant chemotherapy for T4 tumor of the colon cancer. Available from: https://ClinicalTrials.gov/show/NCT02777437. Accessed 1119, 2020.
   Google Scholar